This paper is only available as a PDF. To read, Please Download here.
Clinical trials have consistently shown warfarin's high degree of efficacy for stroke
prevention in patients with nonvalvular atrial fibrillation (AF). However, aspirin
therapy may be sufficient for large subgroups of low-risk AF patients. In addition,
many elderly AF patients cannot receive or sustain adjusted-dose warfarin because
of bleeding (minor and major), drug interactions, and other disutility. For such patients,
a safer and easier to administer anticoagulation regimen is desirable. The Stroke
Prevention in Atrial Fibrillation (SPAF) III Study has two components, based on stratification
of patients as high-risk or low-risk for thromboembolism. In high-risk patients, adjusted-dose
warfarin (INR 2.0 to 3.0) is compared with low-intensity, fixed-dose warfarin (INR
1.2 to 1.5 initial dose adjustment) plus aspirin (325 mg/d) in a randomized trial.
Patients categorized as low-risk all receive aspirin 325 mg/d and are followed-up
to assess the reliability and durability of the risk stratification scheme. Medications
are administered open-label. Primary events (ischemic strokes and systemic emboli)
are assessed by a local neurologist and verified by an Events Committee, neither having
knowledge of assigned treatment. Transesophageal echocardiography is obtained at entry,
when possible. High-risk criteria for the 1,044 patients in the randomized trial (mean
age,=72 years) are impaired left ventricular function (45%), systolic blood pressure
>160 mm Hg (32%), prior thromboembolism (38%), and female gender over age 75 years
(24%). The mean INR is 2.4 for adjusted-dose and 1.3 for fixed-dose warfarin, with
mean daily doses of 3.9 mg and 2.1 mg, respectively. Compared with high-risk patients,
those categorized as low-risk (n=892) are younger (mean age, 67 years; P<.001), with lower mean systolic blood pressures, (P<.001), and less ischemic heart disease (P<.001), but similar diastolic blood pressures. Given the large variation in stroke
rate among AF patients, blanket recommendations for antithrombotic prophylaxis of
all AF patients are not optimal. Patient age, gender, left ventricular function, and
systolic blood pressure may be useful markers of the inherent thromboembolic risk
and may influence selection of antithrombotic therapy to prevent stroke in AF patients.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Stroke and Cerebrovascular DiseasesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.Arch Intern Med. 1994; 154: 1449-1457
- Atrial fibrillation and stroke: Three new studies, three remaining question.Arch Intern Med. 1994; 154: 1443-1448
- Atrial fibrillation is an independent risk factor for stroke: The Framingham Study.Stroke. 1991; 22: 983-988
- European Atrial Fibrillation Trial: Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke.Lancet. 1993; 342: 1255-1262
- Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study.Lancet. 1994; 343: 687-691
- The Stroke Prevention in Atrial Fibrillation Study. Final results.Circulation. 1991; 84: 527-539
- Prevention of stroke in atrial fibrillation.N Engl J Med. 1990; 323: 482
- Atrial fibrillation and stroke: Revisiting the dilemmas.Stroke. 1994; 25: 1337-1341
- Antithrombotic therapy in atrial fibrillation.Chest. 1992; 102: 426S-433S
- Guidelines for medical treatment for stroke prevention.Ann Intern Med. 1994; 121: 41-53
- Drugs and surgery in the prevention of ischemic stroke.N Engl J Med. 1995; 332: 238-248
- Prevalence, age distribution and gender of patients with atrial fibrillation. Analysis and implications.Arch Intern Med. 1995; 155: 469-473
- Predictors of thromboembolism in atrial fibrillation. I: clinical features in patients at risk.Ann Intern Med. 1992; 116: 1-5
- Predictors of thromboembolism in atrial fibrillation. II: echocardiographic features in patients at risk.Ann Intern Med. 1992; 116: 6-12
- A differential effect of aspirin for the prevention of stroke in atrial fibrillation.J Stroke Cerebrovasc Dis. 1993; 3: 181-188
- Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study.J Stroke Cerebrovasc Dis. 1995; 5: 147-157
- Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism.Neurology. 1993; 43: 32-36
- Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation.Neurology. 1996; 46: 238-240
- Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention.Am J Med. 1993; 95: 315-328
- Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice.Arch Intern Med. 1994; 154: 1945-1953
- Intracranial traumatic and nontraumatic hemorrhagic complications of warfarin treatment.Acta Neurol Scand. 1995; 91: 208-214
- Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota.Mayo Clin Proc. 1995; 70: 725-733
- Stroke prevention in Atrial Fibrillation II study.Lancet. 1994; 343 ([letter]): 1509
- Oral anticoagulants and intracranial hemorrhage: facts and hypotheses.Stroke. 1995; 26: 1471-1477
- Committee on Echocardiography. Transesophageal echocardiography in nonvalvular atrial fibrillation: standards for acquisition and interpretation.J Am Soc Echocardiogr. 1996; 9: 556-566
- Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery.BMJ. 1987; 295: 1309-1312
- Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized clinical trial.Ann Intern Med. 1990; 112: 423-428
- Efficacy of fixed mini-dose warfarin prophylaxis in total hip replacement.BMJ. 1991; 303: 219-220
- Antithrombotic risk in cardiac disease: an emerging approach based on pathogenesis and risk.Circulation. 1989; 80: 1501-1513
- A comparison of aspirin with placebo in patients treated with warfarin and heart valve replacement.N Engl J Med. 1993; 329: 524-529
- Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole.Am J Cardiol. 1983; 51: 1537-1541
- Randomized controlled trial of low-dose warfarin in the primary prevention of ischemic heart disease in men at high risk: design and pilot study.Eur Heart J. 1988; 9: 836-843
- Human gastromucosal bleeding induced by low dose aspirin, but not warfarin.BMJ. 1989; 298: 496
- Aspirin-induced gastric mucosal damage: prevention by enteric coating and relation to prostaglandins synthesis.Br J Clin Pharmacol. 1991; 32: 77-83
- Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris.N Engl J Med. 1995; 332: 635-641
- Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation.Stroke. 1993; 24: 1360-1365
- Reliance on prothrombin time ratios causes significant errors in anticoagulant therapy.Arch Intern Med. 1992; 152: 278-282
- The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy.J Clin Epidemiol. 1989; 42: 711-718
- Epidemiologic features of chronic atrial fibrillation: The Framingham Study.N Engl J Med. 1982; 306: 1018-1022
Feinberg WM, Kronmal RA, Newman A, et al. Thromboembolic risk factors in an elderly population, with artial fibrilation: The Cardiovascualr Health Study. Submitted for publication.
- Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study.J Am Coll Cardiol. 1995; 25: 452-459
- Left atrial thrombi in nonrheumatic atrial fibrillation: assessment of prevalence by transesophageal echocardiography.Int J Card Imaging. 1993; 9: 65-72
- Influence of blood pressure on left atrial size. The Framingham Study.Hypertension. 1995; 25: 1155-1160
- Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation.Stroke. 1989; 20: 1000-1004
- Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study.Am J Med. 1991; 91: 156-161
- Transesophageal echocardiographic risk factors for stroke are related to gender and age: observations from the SPAF III Study.Circulation. 1995; 92 ([suppl 1, abstr]): I-283
- Clinical and transthoracic echo predictors of left atrial spontaneous echo contrast in patients with nonvalvular atrial fibrillation.Circulation. 1995; 92 ([suppl 1, abstr]): I-284
- Warfarin for atrial fibrillation: the patient's perspective.Arch Intern Med. 1996; 156: 1841-1848
- Factors relevant to preventing embolic stroke in patients with nonrheumatic atrial fibrillation.J Clin Epidemiol. 1991; 44: 551-560
- Comparisons of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3,166 outpatients.J Intern Med. 1994; 236: 299-304
- Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease.Am J Cardiol. 1994; 74: 657-661
- Extracranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation.Thromb Haemostas. 1992; 68: 1-6
- Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.N Engl J Med. 1995; 333: 5-10
Article info
Publication history
Accepted:
December 4,
1996
Received:
January 3,
1996
Footnotes
*Supported by Grant No. R01 NS 24224 from the Division of Stroke and Trauma, National Institute of Neurological Disorders and Stroke, Bethesda, MD.
Identification
Copyright
© 1997 National Stroke Division. Published by Elsevier Inc.
